Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.
Platinum-resistant Recurrent Ovarian Cancer
DRUG: Letrozole combined with anlotinib hydrochloride
ORR, objective response rate, 3 years
PFS, progression-free survival time, 3 years and 5 years|OS, Overall survival, 3 years and 5 years|AE, Adverse event, 3 years and 5 years
The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.The patient has undergone surgery and received â‰¥2 lines of platinum-containing chemotherapy.